kicked off on Monday, with Travere Therapeutics Inc (NASDAQ: TVTX) stock price up 3.70% from the previous day of trading, before settling in for the closing price of $20.53. TVTX’s price has ranged from $5.12 to $25.29 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 13.83%. Meanwhile, its annual earnings per share averaged 70.49%. With a float of $87.41 million, this company’s outstanding shares have now reached $87.45 million.
The extent of productivity of a business whose workforce counts for 385 workers is very important to gauge. In terms of profitability, gross margin is 92.24%, operating margin of -138.0%, and the pretax margin is -137.45%.
Travere Therapeutics Inc (TVTX) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Travere Therapeutics Inc is 1.50%, while institutional ownership is 109.22%. The most recent insider transaction that took place on Feb 12 ’25, was worth 122,356. In this transaction SENIOR VICE PRESIDENT, R&D of this company sold 5,200 shares at a rate of $23.53, taking the stock ownership to the 98,519 shares. Before that another transaction happened on Feb 12 ’25, when Company’s SVP, GC & CORPORATE SECRETARY sold 8,000 for $23.53, making the entire transaction worth $188,240. This insider now owns 89,482 shares in total.
Travere Therapeutics Inc (TVTX) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.2 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 70.49% per share during the next fiscal year.
Travere Therapeutics Inc (NASDAQ: TVTX) Trading Performance Indicators
Here are Travere Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.04. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.10.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.10, a number that is poised to hit -0.55 in the next quarter and is forecasted to reach 0.84 in one year’s time.
Technical Analysis of Travere Therapeutics Inc (TVTX)
The latest stats from [Travere Therapeutics Inc, TVTX] show that its last 5-days average volume of 1.84 million was superior to 1.66 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 92.85%. Additionally, its Average True Range was 1.09.
During the past 100 days, Travere Therapeutics Inc’s (TVTX) raw stochastic average was set at 54.03%, which indicates a significant decrease from 98.57% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 54.71% in the past 14 days, which was lower than the 55.94% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $20.47, while its 200-day Moving Average is $15.22. Now, the first resistance to watch is $21.60. This is followed by the second major resistance level at $21.91. The third major resistance level sits at $22.47. If the price goes on to break the first support level at $20.73, it is likely to go to the next support level at $20.17. The third support level lies at $19.86 if the price breaches the second support level.
Travere Therapeutics Inc (NASDAQ: TVTX) Key Stats
With a market capitalization of 1.89 billion, the company has a total of 88,740K Shares Outstanding. Currently, annual sales are 233,180 K while annual income is -321,550 K. The company’s previous quarter sales were 74,790 K while its latest quarter income was -60,260 K.
